文献速递淋巴瘤

Polatuzumab vedotin联合利妥昔单抗和来那度胺治疗复发或难治性弥漫大B细胞淋巴瘤患者:一项多中心、单臂、1b/2期研究的队列

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
PubMed 文献 · Lancet Haematol · 2024-01-05

这项多中心单臂1b/2期研究评估了Polatuzumab vedotin联合利妥昔单抗和来那度胺(Pola+R+Len)在57例不适合移植的复发或难治性弥漫大B细胞淋巴瘤患者中的安全性和疗效。1b期确认来那度胺推荐2期剂量为20 mg。中位随访11.8个月,独立评审委员会评估的完全缓解率为31%(90% CI 20-43),未达到预设活性阈值,但部分患者获得临床获益且安全性可耐受。

要点

  • Pola+R+Len方案在复发/难治性弥漫大B细胞淋巴瘤中完全缓解率为31%(90% CI 20-43),未达预设活性阈值。
  • 最常见的3-4级不良事件为中性粒细胞减少(61%)和血小板减少(14%),1例治疗相关死亡(中性粒细胞减少性脓毒症)。
  • 来那度胺推荐2期剂量为20 mg,联合利妥昔单抗375 mg/m2和polatuzumab vedotin 1.8 mg/kg。

核心结论

  • Pola+R+Len联合方案未达到预设的活性阈值,但部分复发或难治性弥漫大B细胞淋巴瘤患者获得临床获益,且方案安全性可耐受。

研究设计与样本

  • 多中心、单臂、开放标签1b/2期研究(GO29834),在美国、西班牙和英国19个中心开展。
  • 纳入57例≥18岁、组织学证实CD20阳性复发或难治性弥漫大B细胞淋巴瘤、ECOG体能状态≤2、既往至少接受过一线含抗CD20药物的化学免疫治疗且不适合干细胞移植的患者。
  • 1b期剂量递增阶段18例,2期剂量扩展阶段39例;1b期采用来那度胺递增剂量(10 mg、15 mg、20 mg)确定推荐2期剂量。

主要发现

  • 1b期确认来那度胺推荐2期剂量为20 mg。
  • 中位随访11.8个月(IQR 4.7-25.8),独立评审委员会基于PET-CT评估的完全缓解率为31%(90% CI 20-43)。
  • 最常见的3-4级不良事件为中性粒细胞减少(35/57,61%)和血小板减少(8/57,14%)。
  • 严重不良事件发生于23/57(40%)患者,1例患者死于治疗相关不良事件(中性粒细胞减少性脓毒症)。

关键数值与推荐

  • 诱导治疗:每28天为一周期,共6周期,利妥昔单抗375 mg/m2静脉注射和polatuzumab vedotin 1.8 mg/kg静脉注射于第1天给药,来那度胺口服第1-21天(1b期剂量10 mg、15 mg、20 mg;2期采用推荐剂量20 mg)。
  • 诱导结束时达到完全缓解或部分缓解的患者可接受诱导后治疗:利妥昔单抗375 mg/m2第1天联合来那度胺10 mg/天第1-21天,每28天一周期,最多6周期。
  • 1b期主要安全性目标为通过剂量限制性毒性发生率确定最大耐受剂量;2期主要疗效终点为独立评审委员会基于PET-CT评估的诱导结束时完全缓解率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse large B-cell lymphoma comprises nearly 30% of non-Hodgkin lymphoma cases and patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for stem-cell transplantation have few treatment options and poor prognoses. We aimed to determine whether the novel combination of polatuzumab vedotin in combination with rituximab and lenalidomide (Pola+R+Len) would provide a tolerable treatment option with enhanced antitumour response in patients with relapsed or refractory diffuse large B-cell lymphoma. METHODS: This completed phase 1b/2, open-label, multicentre, single-arm study (GO29834) evaluated the safety and efficacy of Pola+R+Len in patients with relapsed or refractory diffuse large B-cell lymphoma at 19 sites in three countries (USA, Spain, and UK). Patients (≥18 years old) were eligible for inclusion if they had histologically documented CD20-positive relapsed or refractory diffuse large B-cell lymphoma and Eastern Cooperative Oncology Group performance status of 2 or lower, had received at least one previous line of chemoimmunotherapy, including an anti-CD20 agent, and were ineligible for stem-cell transplantation. The dose-escalation phase (1b) used escalating doses of lenalidomide to find the recommended phase 2 dose. Patients received six 28-day cycles of induction treatment with intravenous rituximab 375 mg/m2 and intravenous polatuzumab vedotin 1·8 mg/kg (all cohorts) plus oral lenalidomide at the following doses: 10 mg (cohort A); 15 mg (cohort B); and 20 mg (cohort C). Rituximab and polatuzumab vedotin were administered on day 1 and lenalidomide on days 1-21 of each 28-day cycle. During the dose-expansion phase (2), patients received six 28-day cycles of Pola+R+Len at the recommended phase 2 dose established during dose escalation. In both phases, patients with a complete response or partial response at the end of induction were eligible for post-induction therapy with rituximab 375 mg/m2 on day 1 and lenalidomide 10 mg/day on days 1-21 of each 28-day cycle for a maximum of 6 cycles. The primary safety objective of the dose-escalation phase was identification of the maximum tolerated dose through incidence of dose-limiting toxic effects. The primary efficacy outcome of the dose-expansion phase was Independent Review Committee-assessed complete response rate at end of induction, based on PET-CT. Analyses were conducted in the safety population, which included all patients who received at least one dose of any study drug, and the efficacy population, which included all patients who received at least one dose of any study drug at the recommended phase 2 dose. This study is registered with ClinicalTrials.gov, number NCT02600897. FINDINGS: Between July 11, 2017 and Feb 3, 2020, 57 patients were enrolled (median age 71 years [IQR 60-75]; 38 [67%] were male and 19 (33%) were female; 47 [82%] were not Hispanic or Latino; and the median previous lines of therapy was 2 [IQR 1-3]). 18 participants were included in phase 1b and 39 were included in phase 2. Phase 1b confirmed a 20 mg recommended phase 2 dose for lenalidomide. After a median follow-up of 11·8 months (IQR 4·7-25·8), the complete response rate, as assessed by the Independent Review Committee, was 31% (90% CI 20-43). The most common grade 3-4 adverse events were neutropenia (35 [61%] of 57) and thrombocytopenia (eight [14%] of 57). Serious adverse events were reported in 23 (40%) of 57 patients and one patient died due to a treatment-related adverse event (neutropenic sepsis). INTERPRETATION: Although the combination of Pola+R+Len did not meet the prespecified activity threshold, some patients derived clinical benefit and the regimen had a tolerable safety profile in patients with relapsed or refractory diffuse large B-cell lymphoma. FUNDING: Genentech/F Hoffmann-La Roche.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Abrisqueta P, González-Barca E, Panizo C, et al. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematol. 2024. PMID: 38190832. doi:10.1016/S2352-3026(23)00345-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。